Kintara Therapeutics (NASDAQ:KTRA) CEO Saiid Zarrabian joined Proactive's Stephen Gunnion with details of the company's fiscal 2021 financial results and news that it has closed securities purchase agreements with healthcare-focused institutional investors.
Zarrabian telling Proactive that it is well positioned on the clinical and corporate development fronts and starts the new financial year with a strengthened cash position.